<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689819</url>
  </required_header>
  <id_info>
    <org_study_id>0803305872</org_study_id>
    <nct_id>NCT00689819</nct_id>
  </id_info>
  <brief_title>Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients</brief_title>
  <official_title>Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients in an Urban Emergency Department: Is a Program Focused on Early Detection and Blood Pressure Control Clinically and Cost Effective?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Wood Johnson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will evaluate the clinical and cost effectiveness of a novel, multidisciplinary
      approach to identify and treat pre-clinical cardiac dysfunction (PCCD) in asymptomatic
      hypertensive patients identified in a single center urban emergency department. Premature
      onset of pressure-related cardiac complications of hypertension (especially heart failure)
      has important implications for long-term survival, quality of life and healthcare costs. This
      project will target patients who have already developed pressure-related cardiac structural
      abnormalities yet remain symptom free. These individuals are at tremendous risk for
      progression to clinically overt heart failure and its associated consequences. We hypothesize
      that detection and treatment of patients with hypertension who have pre-clinical structural
      cardiac damage will enable forestallment of the disease process and offer the opportunity to
      reduce the burden of cardiac morbidity associated with hypertension. This project will
      implement a program to prospectively identify PCCD (using echocardiography) and provide
      treatment. At present, the optimal blood pressure goal for patients with PCCD is unknown so
      this study will randomize patients to 2 levels of blood pressure control: &quot;normal&quot;, which is
      consistent with current national guidelines and &quot;intensive&quot;, which will aim for a markedly
      lower blood pressure (&lt; 120/80). Enrolled patients will receive active treatment and
      follow-up for 1 year. At the end of 1 year, we will evaluate: 1) the ability of this program
      to achieve blood pressure goals; 2) the cost effectiveness; and 3) the proportion in each
      blood pressure group who have evidence of disease regression on echocardiography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>To evaluate the ability of this program to produce (as a surrogate for heart failure prevention) a clinically significant difference in blood pressure lowering, health status and quality of life between the 2 treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Prevalence of PCCD</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>To measure the change from baseline to 1 year prevalence of pre-clinical cardiac dysfunction in randomized study patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Hypertension</condition>
  <condition>High Blood Pressure</condition>
  <condition>Ventricular Hypertrophy</condition>
  <condition>Diastolic Dysfunction</condition>
  <condition>Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Blood pressure (BP) target of &lt; 140/90 mmHg (or &lt; 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Blood pressure (BP) target will be &lt; 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Loss</intervention_name>
    <description>Blood pressure (BP) target of &lt; 140/90 mmHg (or &lt; 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Sodium Diet</intervention_name>
    <description>Blood pressure (BP) target of &lt; 140/90 mmHg (or &lt; 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation</intervention_name>
    <description>Blood pressure (BP) target of &lt; 140/90 mmHg (or &lt; 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)</intervention_name>
    <description>Blood pressure (BP) target of &lt; 140/90 mmHg (or &lt; 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 140/90 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Loss</intervention_name>
    <description>Blood pressure (BP) target will be &lt; 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Sodium Diet</intervention_name>
    <description>Blood pressure (BP) target will be &lt; 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation</intervention_name>
    <description>Blood pressure (BP) target will be &lt; 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)</intervention_name>
    <description>Blood pressure (BP) target will be &lt; 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR&lt; 40 ml/min/1.73 m2: a loop diuretic; eGFR&gt; 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for &gt; 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.</description>
    <arm_group_label>BP &lt; 120/80 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure &gt; or = 140/90 after 1 hour

          -  Asymptomatic state as defined by Goldman Specific Activity Scale

        Exclusion Criteria:

          -  Dyspnea (exertional or nocturnal) or chest pain as a primary or secondary chief
             complaint

          -  Prior history of heart failure, coronary artery disease, myocardial infarction,
             cardiomyopathy, valvular heart disease or renal failure (with current, previous, or
             planned future dialysis)

          -  Patients with acute illness or injury which necessitates hospital admission

          -  Standing relationship with usual source of health care (i.e., primary care provider)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip D. Levy, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University Department of Emergency Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>June 14, 2013</results_first_submitted>
  <results_first_submitted_qc>August 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2013</results_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Phillip D. Levy</investigator_full_name>
    <investigator_title>Research Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>Pre-clinical cardiac dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment 1</title>
          <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
        </group>
        <group group_id="P2">
          <title>Treatment 2</title>
          <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment 1</title>
          <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
        </group>
        <group group_id="B2">
          <title>Treatment 2</title>
          <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="8.1"/>
                    <measurement group_id="B2" value="49.6" spread="8.3"/>
                    <measurement group_id="B3" value="49.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life</title>
        <description>To evaluate the ability of this program to produce (as a surrogate for heart failure prevention) a clinically significant difference in blood pressure lowering, health status and quality of life between the 2 treatment groups.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life</title>
          <description>To evaluate the ability of this program to produce (as a surrogate for heart failure prevention) a clinically significant difference in blood pressure lowering, health status and quality of life between the 2 treatment groups.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-7.6" upper_limit="2.1"/>
                    <measurement group_id="O2" value="-4.9" lower_limit="-11.7" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Prevalence of PCCD</title>
        <description>To measure the change from baseline to 1 year prevalence of pre-clinical cardiac dysfunction in randomized study patients.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Prevalence of PCCD</title>
          <description>To measure the change from baseline to 1 year prevalence of pre-clinical cardiac dysfunction in randomized study patients.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8"/>
                    <measurement group_id="O2" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment 1</title>
          <description>This arm will target a blood pressure of &lt; 140/90 mmHg (or &lt; 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.</description>
        </group>
        <group group_id="E2">
          <title>Treatment 2</title>
          <description>This arm will target a more aggressive blood pressure target of &lt; 120/80 mmHg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Despite our best efforts, study retention was hindered by a higher than expected drop-out rate (26.0% overall; 27.7% control and 24.1% intervention).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Phillip Levy, MD</name_or_title>
      <organization>Wayne State University</organization>
      <phone>3139938558</phone>
      <email>plevy@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

